Workflow
重组胶原蛋白之争未休:巨子生物承认局限性,华熙生物送检润百颜
Xin Jing Bao·2025-07-02 01:19

Core Viewpoint - The ongoing debate between two major companies regarding the restructuring of collagen detection methods highlights the industry's need for standardized testing protocols and the challenges posed by varying product quality in the market [1][4][6]. Group 1: Company Actions and Statements - Huaxi Biological published an article asserting the need for industry standards based on testing results, revealing that their product "Runbaiyan" was tested for collagen content using advanced HPLC-HRMS technology, yielding a result of 0.60 mg/g (0.06%) for type III collagen [2][3]. - Huaxi Biological emphasized that their testing method effectively eliminates matrix interference and ensures accurate detection of recombinant collagen, addressing concerns about the reliability of their results [2][3]. - Juzhi Biological acknowledged the limitations of their existing quality standards and testing methods, stating the need for continuous optimization to meet industry advancements and consumer expectations [5][6]. Group 2: Industry Implications - The debate over collagen measurement methods has been ongoing since May, with Huaxi Biological criticizing misleading conclusions from industry reports and calling for a unified testing standard [4][6]. - Juzhi Biological has committed to collaborating with research institutions to enhance detection methods and to gradually disclose key technical parameters and quality control data to foster industry development and transparency [5]. - The lack of a unified detection method has been described as a strategy to evade scrutiny, highlighting the industry's regulatory challenges and the necessity for verifiable solutions [6].